A Multicenter Breast Cancer Biospecimen Registry

Luminist, Inc.0 sites700 target enrollmentFebruary 2016

ConditionsBreast Cancer

Overview

Phase: N/A
Intervention: Not specified
Conditions: Breast Cancer
Sponsor: Luminist, Inc.
Enrollment: 700
Primary Endpoint: Number of patients with untreated newly diagnosed breast cancer.
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This study is being performed to collect blood for the development of noninvasive tests that can screen for or diagnose cancer. Blood samples will be collected from women who are scheduled to have breast biopsies.

Registry

clinicaltrials.gov

Start Date

February 2016

End Date

December 2017

Last Updated

10 years ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

Luminist, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Females of all racial and ethnic groups who are 40 years or older.
•Women must:
•have suspected neoplasm of the breast (BIRADS 4 or 5) based on the results of any breast screening or diagnostic imaging, such as mammogram, and
•be selected or scheduled for a breast biopsy which has not yet been conducted at the time of enrollment.

Exclusion Criteria

•Inability to sign informed consent.
•More than one radiological finding.
•Any current or prior cancer (with the exception of non-melanoma skin cancer or a suspected breast malignancy targeted for biopsy).
•Any known or suspected acute illness or condition - including acute infections - at the time of enrollment or within the previous 30 days.
•Any surgery, hospitalization, or institutionalization (such as in a nursing home) during the previous 3 months.
•Received any experimental therapeutic treatment during the previous 3 months.
•Received any blood product transfusion within the previous 3 months.
•Use of illegal drugs during the previous 3 months.
•Pregnant or nursing at the time of enrollment or in the preceding 12 months.